At a glance
- Anamorelin is not an FDA-approved drug: Drugs@FDA has no record of it.
- PubMed lists 176 publications mentioning it, including 10 randomized controlled trials and 6 animal-only studies.
- ClinicalTrials.gov lists 14 registered studies testing it (2 active).
- FDA's adverse event system (FAERS) holds 207 reports mentioning it; 204 classified as serious. Reports do not prove causation.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
No application found in Drugs@FDA, FDA's database of approved drugs.
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- Exploring Inhibitory Impacts of Anamorelin on Colorectal Cancer Proliferation via Regulation of Transketolase.
- Predictors of anamorelin discontinuation in patients with cancer-associated cachexia undergoing chemotherapy: A retrospective observational study.
- Predictors of 12-Week Anamorelin Treatment Continuation in Gastrointestinal Cancer Cachexia: A Single-Center, Retrospective Study.
- Correction to 'A Prospective Observational Study of Anamorelin During Chemoimmunotherapy in Non-Small Cell Lung Cancer With Cachexia (SPIRAL-ANA)'.
- Predictors of early discontinuation and therapeutic response to anamorelin in patients with cancer cachexia: A retrospective study.
- Gamma-glutamyl Transferase and Triglycerides Associated with an Early Food Intake Response to Anamorelin in Gastrointestinal Cancer Cachexia.
- A Prospective Observational Study of Anamorelin During Chemoimmunotherapy in Non-Small Cell Lung Cancer With Cachexia (SPIRAL-ANA).
- Trends in the Use of Anamorelin Hydrochloride for Cancer Cachexia: Examining the Timing of Anamorelin Initiation.
- Association between anamorelin therapy and renal function in patients with cancer cachexia: a propensity score-matched retrospective study.
- Cost-Effectiveness Analysis of Anamorelin and Olanzapine for Cancer Cachexia in Non-Small Cell Lung Cancer Patients in Japan.
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
- Registered
- 14
- Active
- 2
- With posted results
- 9
Conditions studied
Show 4 more studies
| Study | Status | Phase | Start |
|---|---|---|---|
| Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer | Completed | Phase 2 | Mar 2008 |
| Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia | Completed | Phase 2 | Sep 2006 |
| Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia. | Completed | Phase 2 | Nov 2005 |
| Safety and Efficacy of RC-1291 HCl in Patients With Cancer Related Anorexia and Weight Loss | Completed | Phase 2 | Jun 2005 |
All 14 studies on ClinicalTrials.gov ↗
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
- Reports
- 207
- Serious
- 204
- With death outcome
- 69
Most reported reactions
Adverse event reports do not prove that the substance caused these effects. Side effects not listed here may still occur. Reaction terms are MedDRA terms as reported to FAERS.
Source: FDA FAERS (FAERS data as of July 30, 2026) · verified October 30, 2026 · API query
Change history
No changes since monitoring began on October 30, 2026.